NicOx Says Au Revoir To Phase II Hypertension Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
French drug maker’s treatment for hypertension stemming from chronic liver disease fails to show efficacy.
You may also be interested in...
NicOx On Track For First-Quarter 2009 Naproxcinod Filing
French firm aims to become a fully integrated biopharma within three years, with commercial operations in the U.S. and major EU countries.
NicOx On Track For First-Quarter 2009 Naproxcinod Filing
French firm aims to become a fully integrated biopharma within three years, with commercial operations in the U.S. and major EU countries.
NicOx Osteoarthritis NDA Filing On Track Following FDA Correspondence
FDA says a clinical cardiovascular outcomes trial is not required.